Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Baird Medical Investment Holdings (BDMD) Current Assets (2023 - 2025)

Baird Medical Investment Holdings has reported Current Assets over the past 3 years, most recently at $55.0 million for Q4 2025.

  • For Q4 2025, Current Assets fell 10.5% year-over-year to $55.0 million; the TTM value through Dec 2025 reached $55.0 million, down 10.5%, while the annual FY2025 figure was $55.0 million, 10.5% down from the prior year.
  • Current Assets for Q4 2025 was $55.0 million at Baird Medical Investment Holdings, down from $60.7 million in the prior quarter.
  • Over five years, Current Assets peaked at $61.4 million in Q4 2024 and troughed at $40.1 million in Q4 2023.
  • A 3-year average of $54.3 million and a median of $57.9 million in 2025 define the central range for Current Assets.
  • Biggest five-year swings in Current Assets: surged 53.22% in 2024 and later dropped 10.5% in 2025.
  • Year by year, Current Assets stood at $40.1 million in 2023, then soared by 53.22% to $61.4 million in 2024, then dropped by 10.5% to $55.0 million in 2025.
  • Business Quant data shows Current Assets for BDMD at $55.0 million in Q4 2025, $60.7 million in Q2 2025, and $61.4 million in Q4 2024.